Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient
Abstract
1. Introduction
2. Case Description
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Khanam, R.; Ashruf, O.S.; Waqar, S.H.B.; Shah, Z.; Batool, S.; Mehreen, R.; Pachika, P.; Roksana, Z.; Rehman, M.E.U.; Anwer, F. The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review. Antibodies 2023, 12, 38. [Google Scholar] [CrossRef]
- Zhao, J.; Ren, Q.; Liu, X.; Guo, X.; Song, Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: Latest updates from ASCO 2023 Annual Meeting. J. Hematol. Oncol. 2023, 16, 92. [Google Scholar] [CrossRef]
- Moreau, P.; Garfall, A.L.; van de Donk, N.; Nahi, H.; San-Miguel, J.F.; Oriol, A.; Nooka, A.K.; Martin, T.; Rosinol, L.; Chari, A.; et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 2022, 387, 495–505. [Google Scholar] [CrossRef]
- Zaja, F.; Lucchini, E.; Poiani, M.; Sbisa, E.; Mohamed, S.; De Bellis, E.; Caizzi, M.; Palmieri, C.; Loiacono, S.; Granzotto, M.; et al. Teclistamab salvage therapy for multiple myeloma relapse after allogeneic hemopoietic stem cell transplant: A case report. Am. J. Hematol. 2024, 99, E29–E31. [Google Scholar] [CrossRef]
- Midha, S.; Hartley-Brown, M.A.; Mo, C.C.; Hossain, S.; Nadeem, O.; O’Donnell, E.K.; Bianchi, G.; Sperling, A.S.; Laubach, J.P.; Richardson, P.G. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. Expert Opin. Drug Saf. 2023, 22, 1049–1071. [Google Scholar] [CrossRef] [PubMed]
- Pan, D.; Richter, J. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody. Cancer Manag. Res. 2023, 15, 741–751. [Google Scholar] [CrossRef] [PubMed]
- Crombie, J.L.; Graff, T.; Falchi, L.; Karimi, Y.H.; Bannerji, R.; Nastoupil, L.; Thieblemont, C.; Ursu, R.; Bartlett, N.; Nachar, V.; et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood 2024, 143, 1565–1575. [Google Scholar] [CrossRef]
- Kazandjian, D.; Kowalski, A.; Landgren, O. T cell redirecting bispecific antibodies for multiple myeloma: Emerging therapeutic strategies in a changing treatment landscape. Leuk. Lymphoma 2022, 63, 3032–3043. [Google Scholar] [CrossRef] [PubMed]
- Ludwig, H.; Terpos, E.; van de Donk, N.; Mateos, M.V.; Moreau, P.; Dimopoulos, M.A.; Delforge, M.; Rodriguez-Otero, P.; San-Miguel, J.; Yong, K.; et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: A consensus report of the European Myeloma Network. Lancet Oncol. 2023, 24, e255–e269. [Google Scholar] [CrossRef]
- Frerichs, K.A.; Verkleij, C.P.M.; Mateos, M.V.; Martin, T.G.; Rodriguez, C.; Nooka, A.; Banerjee, A.; Chastain, K.; Perales-Puchalt, A.; Stephenson, T.; et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: Importance of immunoglobulin supplementation. Blood Adv. 2024, 8, 194–206. [Google Scholar] [CrossRef]
- Mohan, M.; Monge, J.; Shah, N.; Luan, D.; Forsberg, M.; Bhatlapenumarthi, V.; Balev, M.; Patwari, A.; Cheruvalath, H.; Bhutani, D.; et al. Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study. Blood Cancer J. 2024, 14, 35. [Google Scholar] [CrossRef] [PubMed]
- Mohan, M.; Chakraborty, R.; Bal, S.; Nellore, A.; Baljevic, M.; D’Souza, A.; Pappas, P.G.; Berdeja, J.G.; Callander, N.; Costa, L.J. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Br. J. Haematol. 2023, 203, 736–746. [Google Scholar] [CrossRef] [PubMed]
- Liu, T.; Schwartz, T.; Chebolu, A.P.; Tsui, J.C.; Bhatt, N.; Scoles, D. Teclistamab-Associated Sclerouveitis with Hypopyon. Retin. Cases Brief Rep. 2023. [Google Scholar] [CrossRef]
- Lutfi, F.; Abdallah, A.O.; Nashatizadeh, M.; Ahmed, N.; Nelson, M.; Hamideh, J.; Mahmoudjafari, Z.; Shune, L. Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity. Cureus 2023, 15, e49192. [Google Scholar] [CrossRef]
- Dalla-Pozza, P.; Hentzien, M.; Allavena, C.; Doe de Maindreville, A.; Bouiller, K.; Valantin, M.A.; Lafont, E.; Zaegel-Faucher, O.; Cheret, A.; Martin-Blondel, G.; et al. Progressive multifocal leukoencephalopathy in patients with immunovirological control and at least 6 months of combination antiretroviral therapy. AIDS 2022, 36, 539–549. [Google Scholar] [CrossRef] [PubMed]
- Pavlovic, D.; Patera, A.C.; Nyberg, F.; Gerber, M.; Liu, M.; Progressive Multifocal Leukeoncephalopathy, C. Progressive multifocal leukoencephalopathy: Current treatment options and future perspectives. Ther. Adv. Neurol. Disord. 2015, 8, 255–273. [Google Scholar] [CrossRef]
- Brigo, F.; Pagani, E.; Tezzon, F.; Masi, E.; Nardone, R. Lenalidomide-associated progressive multifocal leukoencephalopathy. Leuk. Lymphoma 2017, 58, 2514–2515. [Google Scholar] [CrossRef]
- Hoeynck, B.W.; Cohen, A.D.; Stadtmauer, E.A.; Susanibar-Adaniya, S.P.; Vogl, D.T.; Waxman, A.J.; Bardsley, M.; Le, S.; LaMaestra, L.; Garfall, A.L. Progressive multifocal leukoencephalopathy in multiple myeloma. Eur. J. Haematol. 2023, 110, 322–329. [Google Scholar] [CrossRef]
- Varghese, N.; Dhar, D.; Mukherjee, A.; Nashi, S.; Nandeesh, B.N.; Kulkarni, G.B.; Taallapalli, A.V.R.; Alladi, S. The Connecting Link: A Case Report of the First Association of COVID-19 and Progressive Multifocal Leukoencephalopathy. Ann. Indian Acad. Neurol. 2023, 26, 1028–1030. [Google Scholar] [CrossRef]
- Pessoa-Goncalves, Y.M.; Farnesi-de-Assuncao, T.S.; de Sousa, M.A.D.; Ferreira, L.M.J.; Matos, B.S.; Borges, A.V.B.; Oliveira-Scussel, A.C.M.; da Silva, A.E.; Oliveira, C.J.F.; da Silva, M.V.; et al. Progressive multifocal leukoencephalopathy triggered by COVID-19 in a previously asymptomatic person living with undiagnosed HIV infection. Int. J. Infect. Dis. 2023, 137, 1–3. [Google Scholar] [CrossRef]
- Borrelli, S.; Dachy, B.; Gazagnes, M.D.; Du Pasquier, R. Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia. J. Neurovirol. 2021, 27, 510–513. [Google Scholar] [CrossRef] [PubMed]
- D’Apolito, M.; Rispoli, M.G.; Ajdinaj, P.; Digiovanni, A.; Tomassini, V.; Gentile, L.; De Luca, G. Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: A diagnostic challenge. Neurol. Sci. 2023, 44, 1141–1146. [Google Scholar] [CrossRef]
- Hatchwell, E.; Smith, E.B., 3rd; Jalilzadeh, S.; Bruno, C.D.; Taoufik, Y.; Hendel-Chavez, H.; Liblau, R.; Brassat, D.; Martin-Blondel, G.; Wiendl, H.; et al. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies. Front. Neurol. 2022, 13, 1016377. [Google Scholar] [CrossRef] [PubMed]
- Berger, J.R.; Aksamit, A.J.; Clifford, D.B.; Davis, L.; Koralnik, I.J.; Sejvar, J.J.; Bartt, R.; Major, E.O.; Nath, A. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013, 80, 1430–1438. [Google Scholar] [CrossRef]
- Ferro, J.M.; Aguiar de Sousa, D. Cerebral Venous Thrombosis: An Update. Curr. Neurol. Neurosci. Rep. 2019, 19, 74. [Google Scholar] [CrossRef] [PubMed]
- Lasocki, A.; Gangatharan, S.; Gaillard, F.; Harrison, S.J. Intracranial involvement by multiple myeloma. Clin. Radiol. 2015, 70, 890–897. [Google Scholar] [CrossRef]
- Patel, P.; DeCuir, J.; Abrams, J.; Campbell, A.P.; Godfred-Cato, S.; Belay, E.D. Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review. JAMA Netw. Open 2021, 4, e2126456. [Google Scholar] [CrossRef]
- Nooka, A.K.; Rodriguez, C.; Mateos, M.V.; Manier, S.; Chastain, K.; Banerjee, A.; Kobos, R.; Qi, K.; Verona, R.; Doyle, M.; et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer 2024, 130, 886–900. [Google Scholar] [CrossRef]
- Chari, A.; Minnema, M.C.; Berdeja, J.G.; Oriol, A.; van de Donk, N.; Rodriguez-Otero, P.; Askari, E.; Mateos, M.V.; Costa, L.J.; Caers, J.; et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N. Engl. J. Med. 2022, 387, 2232–2244. [Google Scholar] [CrossRef]
- Lesokhin, A.M.; Tomasson, M.H.; Arnulf, B.; Bahlis, N.J.; Miles Prince, H.; Niesvizky, R.; Rodriotaguez-Otero, P.; Martinez-Lopez, J.; Koehne, G.; Touzeau, C.; et al. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat. Med. 2023, 29, 2259–2267. [Google Scholar] [CrossRef]
- Lancman, G.; Parsa, K.; Kotlarz, K.; Avery, L.; Lurie, A.; Lieberman-Cribbin, A.; Cho, H.J.; Parekh, S.S.; Richard, S.; Richter, J.; et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023, 4, 440–451. [Google Scholar] [CrossRef]
- Raje, N.; Anderson, K.; Einsele, H.; Efebera, Y.; Gay, F.; Hammond, S.P.; Lesokhin, A.M.; Lonial, S.; Ludwig, H.; Moreau, P.; et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer J. 2023, 13, 116. [Google Scholar] [CrossRef]
- Girmenia, C.; Cavo, M.; Offidani, M.; Scaglione, F.; Corso, A.; Di Raimondo, F.; Musto, P.; Petrucci, M.T.; Barosi, G. Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Blood Rev. 2019, 34, 84–94. [Google Scholar] [CrossRef]
- Longhitano, A.P.; Slavin, M.A.; Harrison, S.J.; Teh, B.W. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap. Blood Rev. 2021, 49, 100810. [Google Scholar] [CrossRef]
- Brust, J.C.M.; McGowan, J.P.; Fine, S.M.; Merrick, S.T.; Radix, A.E.; Vail, R.M.; Stevens, L.C.; Hoffmann, C.J.; Gonzalez, C.J. Management of Immune Reconstitution Inflammatory Syndrome (IRIS); New York State Department of Health AIDS Institute Clinical Guidelines: Baltimore, MD, USA, 2021.
- Sun, H.Y.; Singh, N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr. Opin. Infect. Dis. 2009, 22, 394–402. [Google Scholar] [CrossRef]
Category | Details |
---|---|
Demographic information | |
Age | 72 years old |
Gender | Male |
Smoking status | Current smoker |
Diagnosis date | Initial MRI: day 1082 before hospitalization |
Initial diagnosis | Multiple Myeloma, kappa light chain-restricted |
Cytogenetic features | Monosomy 13, 14, 17; del17p |
High-risk mutations | TP53 deletion |
Previous treatments | - Induction with RVD (started on day 1017 before hospitalization) |
- Autologous stem cell transplant (day 884 before hospitalization) | |
- Switched to daratumumab, carfilzomib, dexamethasone (day 681 before hospitalization) | |
- Pomalidomide added to daratumumab, carfilzomib, dexamethasone (day 343 before hospitalization) | |
- Pomalidomide added (day 343 before hospitalization) | |
- Switched to ixazomib, cyclophosphamide, dexamethasone (day 198 before hospitalization) | |
- Teclistamab (day 5 before hospitalization) |
Parameter | Reference Range | Pre-Hospitalization Post-Teclistamab (Day-5) | Hospitalization Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 |
---|---|---|---|---|---|---|---|---|---|
WBC (×109/L) | 4.2–10.0 | 7.2 | 8.0 | 6.8 | 7.4 | 6.8 | 8.1 | 9.8 | 12.5 (H) |
Neutrophils (Absolute) (×109/L) | 1.9–6.7 | - | 6.3 | 6.2 | 5.4 | 4.8 | 5.7 | 7.4 (H) | 9.4 |
Neutrophils (%) | - | 78.3 | 91.3 | 73.0 | 70.5 | 71.4 | 75.1 | 74.9 | |
Lymphocytes (Absolute) (×109/L) | 1.0–3.3 | - | 0.5 (L) | 0.4 (L) | 0.6 (L) | 0.6 (L) | 0.8 (L) | 0.8 (L) | 1 |
Immature Granulocytes (%) | 1.0–3.3 | - | 0.6 | 0.4 | 0.4 | 0.7 | 0.7 | 1.1 | 1.2 |
Lymphocytes (%) | - | 6.4 | 5.1 | 7.4 | 8.2 | 9.4 | 8.4 | 8.1 | |
Monocytes (%) | - | 13.7 | 3.2 | 17.2 | 17.1 | 16.1 | 13.6 | 13.6 | |
Eosinophils (%) | - | 0.9 | 0.0 | 1.9 | 3.1 | 2.0 | 1.6 | 1.6 | |
Basophils (%) | - | 0.1 | 0.0 | 0.1 | 0.4 | 0.4 | 0.2 | 0.6 | |
RBC (×1012/L) | 4.50–5.60 | 4.00 (L) | 4.03 (L) | 3.75 (L) | 3.50 (L) | 3.47 (L) | 3.75 (L) | 4.08 (L) | 4.20 (L) |
Hemoglobin (g/dL) | 13.4–16.0 | 13.1 (L) | 13.1 (L) | 12.2 (L) | 11.3 (L) | 11.1 (L) | 12.0 (L) | 13.4 | 13.7 |
Hematocrit (%) | 41.2–51.0 | 38.0 (L) | 39.0 (L) | 35.6 (L) | 33.3 (L) | 33.0 (L) | 35.5 (L) | 38.3 (L) | 39.5 (L) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Arvanitis, P.; Farmakiotis, D.; Pelcovits, A. Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient. Curr. Oncol. 2024, 31, 2670-2678. https://doi.org/10.3390/curroncol31050202
Arvanitis P, Farmakiotis D, Pelcovits A. Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient. Current Oncology. 2024; 31(5):2670-2678. https://doi.org/10.3390/curroncol31050202
Chicago/Turabian StyleArvanitis, Panos, Dimitrios Farmakiotis, and Ari Pelcovits. 2024. "Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient" Current Oncology 31, no. 5: 2670-2678. https://doi.org/10.3390/curroncol31050202
APA StyleArvanitis, P., Farmakiotis, D., & Pelcovits, A. (2024). Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient. Current Oncology, 31(5), 2670-2678. https://doi.org/10.3390/curroncol31050202